Autopsy and Case Reports (Mar 2018)

Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma

  • Maria João Marques Ribeiro,
  • Teresa Alonso,
  • Pablo Gajate,
  • Javier Molina,
  • Arantzazu Barquin,
  • Cristian Perna,
  • Enrique Grande

DOI
https://doi.org/10.4322/acr.2018.005
Journal volume & issue
Vol. 8, no. 1

Abstract

Read online

Chemotherapy is considered “state of the art” for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor activity.

Keywords